This selection of resources is designed for healthcare professionals to support patients with relapsing forms of multiple sclerosis (RMS) throughout their KESIMPTA® (ofatumumab) journey.

You can download these materials and share them with your healthcare team and patients.

Getting Started with KESIMPTA®

A guide to support you in initiating KESIMPTA® for patients switching from oral therapies, self-administered injectables or I/V infusions.


Click & Go with KESIMPTA®

A guide to support you in educating
your patients on administering
KESIMPTA® with the Senoready® Pen.


KESIMPTA® Patient Booklet

This booklet provides useful information for patients starting treatment with KESIMPTA®, including how to take KESIMPTA®, how to store KESIMPTA® and important treatment information.


KESIMPTA® Adherence Diary

This is an adherence diary to ensure that patients are getting the most out of their KESIMPTA® treatment by helping them to track their injection days and to follow the dosing schedule exactly as prescribed


Click here for Product Information

Rate this content: 
No votes yet
IE224173 July 2022
▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: Adverse events could also be reported to Novartis preferably via or by email: [email protected] or by calling 01 2080 612.

Ask Speakers


Medical Information Request